

NOVEL STRATEGIES IN ER-POSITIVE BREAST CANCER: AN EVOLVING CASCADE OF TREATMENTS FOR LONG-TERM DISEASE CONTROL



Friday, 5 May 2017
17.00 – 18.30

Silver Hall



This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

CHAIR

MARTINE PICCART, MD, PHD
Jules Bordet Institute
Brussels, Belgium

FACULTY

FABRICE ANDRÉ, MD, PHD
Gustave Roussy
Villejuif, France

ANGELO DI LEO, MD, PHD
Istituto Toscani Tumori, Hospital of Prato
Prato, Italy

PETER SCHMID, MD, PHD, FRCP
Barts Cancer Institute
Queen Mary University of London
London, United Kingdom

TARGET AUDIENCE

This educational activity is specifically designed for oncologists, translational scientists, and other healthcare professionals who wish to understand some of the latest developments in treatments (ER)-positive breast cancer.

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.

AGENDA

- 17.00 Welcome, introduction, and "Beat the Expert" clinical quiz
Martine Piccart, MD, PhD
- 17.10 Endocrine sensitivity and resistance: Are we close to solving the mystery?
Peter Schmid, MD, PhD, FRCP
- 17.25 Questions from the audience
- 17.30 Taking the foot off the gas: Clinical consequences of cell cycle inhibition in ER-positive metastatic breast cancer
Angelo Di Leo, MD, PhD
- 17.45 Questions from the audience
- 17.50 Signaling pathway inhibition for ER-positive advanced breast cancer: New targets making a difference
Fabrice André, MD, PhD
- 18.05 Questions from the audience
- 18.10 The times they are a changin': New opportunities to improve outcomes in ER-positive advanced breast cancer
Martine Piccart, MD, PhD
- 18.25 prIME Points™
Martine Piccart, MD, PhD
- 18.30 Adjourn

